Search Results - "D'Amico, Ronald"

Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection by D’Amico, Ronald, Margolis, David A.

“…PURPOSE OF REVIEWLong-acting formulations of antiretrovirals have the potential to reshape the treatment paradigm for HIV infection. Emerging evidence…”
Get full text

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study by Overton, Edgar T, Richmond, Gary, Rizzardini, Giuliano, Thalme, Anders, Girard, Pierre-Marie, Wong, Alexander, Porteiro, Norma, Swindells, Susan, Reynes, Jacques, Noe, Sebastian, Harrington, Conn, Español, Carlos Martín, Acuipil, Carolina, Aksar, Asma, Wang, Yuanyuan, Ford, Susan L, Crauwels, Herta, van Eygen, Veerle, Van Solingen-Ristea, Rodica, Latham, Christine L, Thiagarajah, Shanker, D’Amico, Ronald, Smith, Kimberly Y, Vandermeulen, Kati, Spreen, William R

“…Abstract Background Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the…”
Get full text

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects by Han, Kelong, Baker, Mark, Lovern, Mark, Paul, Prokash, Xiong, Yuan, Patel, Parul, Moore, Katy P., Seal, Ciara S., Cutrell, Amy G., D'Amico, Ronald D., Benn, Paul D., Landovitz, Raphael J., Marzinke, Mark A., Spreen, William R., Ford, Susan L.

“…Aim To characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic…”
Get full text

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults by Letendre, Scott L, Mills, Anthony, Hagins, Debbie, Swindells, Susan, Felizarta, Franco, Devente, Jerome, Bettacchi, Christopher, Lou, Yu, Ford, Susan, Sutton, Kenneth, Shaik, Jafar Sadik, Crauwels, Herta, D’Amico, Ronald, Patel, Parul

“…Abstract Background Long-acting (LA) formulations of cabotegravir, an HIV integrase inhibitor, and rilpivirine, an NNRTI, are in development as monthly or 2…”
Get full text

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials by Elliot, Emilie R, Polli, Joseph W, Patel, Parul, Garside, Louise, Grove, Richard, Barnett, Vincent, Roberts, Jeremy, Byrapuneni, Sri, Crauwels, Herta, Ford, Susan L, Van Solingen-Ristea, Rodica, Birmingham, Eileen, D'Amico, Ronald, Baugh, Bryan, van Wyk, Jean

“…Cabotegravir plus rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of human immunodeficiency virus-1…”
Get full text

Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study by Mussini, Cristina, Cazanave, Charles, Adachi, Eisuke, Eu, Beng, Alonso, Marta Montero, Crofoot, Gordon, Chounta, Vasiliki, Kolobova, Irina, Sutton, Kenneth, Sutherland-Phillips, Denise, Urbaityte, Rimgaile, Ehmann, Alice, Scherzer, Jenny, de Los Rios, Patricia, D'Amico, Ronald, Spreen, William, van Wyk, Jean

“…SOLAR (NCT04542070; registered 2020-09-09) is a Phase 3b study that demonstrated the noninferior virological efficacy of switching to cabotegravir +…”
Get full text

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine by Jeffrey, Jerry L, St Clair, Marty, Wang, Ping, Wang, Chunfu, Li, Zhufang, Beloor, Jagadish, Talarico, Christine, Fridell, Robert, Krystal, Mark, White, C Thomas, Griffith, Sandy, D'Amico, Ronald, Smith, Kimberly, Van Eygen, Veerle, Vingerhoets, Johan, Vandermeulen, Kati, Spreen, William, van Lunzen, Jan

“…The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for…”
Get full text

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure by Orkin, Chloe, Schapiro, Jonathan M, Perno, Carlo F, Kuritzkes, Daniel R, Patel, Parul, DeMoor, Rebecca, Dorey, David, Wang, Yongwei, Han, Kelong, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L, Latham, Christine L, St. Clair, Marty, Polli, Joseph W, Vanveggel, Simon, Vandermeulen, Kati, D’Amico, Ronald, Garges, Harmony P, Zolopa, Andrew, Spreen, William R, van Wyk, Jean, Cutrell, Amy G

“…Abstract Background Previously reported post hoc multivariable analyses exploring predictors of confirmed virologic failure (CVF) with cabotegravir +…”
Get full text

Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE) by Czarnogorski, Maggie, Garris, Cindy P., Dalessandro, Marybeth, D'Amico, Ronald, Nwafor, Toyin, Williams, Will, Merrill, Deanna, Wang, YuanYuan, Stassek, Larissa, Wohlfeiler, Michael B., Sinclair, Gary I., Mena, Leandro A., Thedinger, Blair, Flamm, Jason A., Benson, Paul, Spreen, William R.

“…Introduction CUSTOMIZE evaluated the implementation of long‐acting (LA) cabotegravir + rilpivirine, a novel healthcare provider–administered injectable…”
Get full text

Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study by Garris, Cindy P., Czarnogorski, Maggie, Dalessandro, Marybeth, D'Amico, Ronald, Nwafor, Toyin, Williams, Will, Merrill, Deanna, Wang, YuanYuan, Stassek, Larissa, Wohlfeiler, Michael B., Sinclair, Gary I., Mena, Leandro A., Thedinger, Blair, Flamm, Jason A., Benson, Paul, Spreen, William R.

“…Introduction The CUSTOMIZE hybrid III implementation‐effectiveness study evaluated implementation of once‐monthly long‐acting (LA) cabotegravir + rilpivirine…”
Get full text

Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations by Gutner, Cassidy A., Hocqueloux, Laurent, Jonsson‐Oldenbüttel, Celia, Vandekerckhove, Linos, Welzen, Berend J., Slama, Laurence, Crusells‐Canales, María, Sierra, Julián Olalla, DeMoor, Rebecca, Scherzer, Jenny, Ait‐Khaled, Mounir, Bontempo, Gilda, Gill, Martin, Patel, Natasha, D'Amico, Ronald, Hove, Kai, Baugh, Bryan, Barnes, Nicola, Hadi, Monica, Low, Emma L., Anand, Savita Bakhshi, Hamilton, Alison, Garges, Harmony P., Czarnogorski, Maggie

“…Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological…”
Get full text

Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration by Teichner, Paula, Chamay, Nadine, Elliot, Emilie, Pascual-Bernáldez, Miguel, Merrill, Deanna, Garris, Cindy, D'Amico, Ronald, Felizarta, Cecy, Torres, Emma, Van Solingen-Ristea, Rodica, Baugh, Bryan, Patel, Parul, Vannappagari, Vani, Dakhia, Samia, Polli, Joseph W, Garside, Louise, Grove, Richard, Thiagarajah, Shanker, Birmingham, Eileen, van Wyk, Jean

“…Cabotegravir (CAB) + rilpivirine (RPV) dosed monthly or every 2 months is a complete long-acting (LA) regimen for the maintenance of human immunodeficiency…”
Get full text

HIV-1 Protease Inhibitors and Clinical Malaria: a Secondary Analysis of the AIDS Clinical Trials Group A5208 Study by PORTER, Kimberly A, COLE, Stephen R, D'AMICO, Ronald, SAWE, Frederick K, SIIKA, Abraham, STRINGER, Elizabeth, CURRIER, Judith S, CHIPATO, Tsungai, SALATA, Robert, MCCARTHY, James S, MESHNICK, Steven R, ERON, Joseph J, YU ZHENG, HUGHES, Michael D, LOCKMAN, Shahin, POOLE, Charles, SKINNER-ADAMS, Tina S, HOSSEINIPOUR, Mina, SHAFFER, Doug

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment by Skinner-Adams, Tina S, Butterworth, Alice S, Porter, Kimberly A, D'Amico, Ronald, Sawe, Fred, Shaffer, Doug, Siika, Abraham, Hosseinipour, Mina C, Stringer, Elizabeth, Currier, Judith S, Chipato, Tsungai, Salata, Robert, Lockman, Shahin, Eron, Joseph J, Meshnick, Steven R, McCarthy, James S

“…HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients…”
Get full text

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine by Patel, Parul, Teichner, Paula, Elliot, Emilie, Boffito, Marta, Murray, Milena, Polli, Joseph W., Baker, Mark, Ford, Susan L., Han, Kelong, Russu, Alberto, Crauwels, Herta, D’Amico, Ronald D., Spreen, William R., van Wyk, Jean

“…Cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting (LA) injectable regimen recommended by treatment guidelines for the maintenance of…”
Get full text

Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067 by D'Amico, Ronald, Yang, Yijun, Mildvan, Donna, Evans, Scott R, Schnizlein-Bick, Carol T, Hafner, Richard, Webb, Nancy, Basar, Michael, Zackin, Robert, Jacobson, Mark A

“…Although initiation of potent antiretroviral therapy (ART) has significantly improved immune perturbations in individuals with AIDS, it is unclear which…”
Get full text

Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants by Han, Kelong, Gevorkyan, Hakop, Sadik Shaik, Jafar, Crauwels, Herta, Leemereise, Claudia, Bontempo, Gilda, Win, Beta, Chounta, Vasiliki, Seal, Ciara, DeMoor, Rebecca, D'Amico, Ronald, Spreen, William R, Ford, Susan L

“…Cabotegravir + rilpivirine administered via intramuscular gluteal injections is the first complete long-acting (LA) regimen approved for maintaining HIV-1…”
Get full text

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials by Rizzardini, Giuliano, Overton, Edgar T., Orkin, Chloe, Swindells, Susan, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Girard, Pierre-Marie, Oka, Shinichi, Andrade-Villanueva, Jaime F., Richmond, Gary J., Baumgarten, Axel, Masiá, Mar, Latiff, Gulam, Griffith, Sandy, Harrington, Conn M., Hudson, Krischan J., St. Clair, Marty, Talarico, Christine L., Patel, Parul, Cutrell, Amy, Van Eygen, Veerle, D'Amico, Ronald, Mrus, Joseph M., Wu, Sterling, Ford, Susan L., Chow, Ken, Roberts, Jeremy, Wills, Angela, Walters, Nicola, Vanveggel, Simon, Van Solingen-Ristea, Rodica, Crauwels, Herta, Smith, Kimberly Y., Spreen, William R., Margolis, David A.

“…Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2…”
Get full text

Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials by Elliot, Emilie, Polli, Joseph W, Patel, Parul, Garside, Louise, Grove, Richard, Barnett, Vince, Roberts, Jeremy, Byrapuneni, Sri, Crauwels, Herta, Ford, Susan L, Van Solingen-Ristea, Rodica, Birmingham, Eileen, D'Amico, Ronald, Baugh, Bryan, van Wyk, Jean

“…Cabotegravir + rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of HIV-1 virologic suppression. This…”
Get full text

Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy by D'Amico, Ronald, Cenoz Gomis, Santiago, Moodley, Riya, Van Solingen‐Ristea, Rodica, Baugh, Bryan, Van Landuyt, Erika, Van Eygen, Veerle, Min, Sherene, Cutrell, Amy, Foster, Caroline, Chilton, Daniella, Allard, Sabine D., Ruiter, Annemiek

“…Objectives Physicians could request compassionate use of oral and long‐acting (LA) cabotegravir + rilpivirine for people living with HIV‐1 under a…”
Get full text